12:30 - 12:50

Novel strategies to achieve a sustainable treatment
实现可持续治疗的新策略

13:00 - 13:20

Impact of lifestyle to sustain health and prevent IBD
生活方式对维持健康和预防IBD的影响

14:30 - 15:10

IBD care in 2025:
2025年 IBD 管理：
Novel Drugs
新药
Selection of Drugs
药物选择
Strategies
策略

15:40 - 16:00

ChatGPT, Dr. Google – helpful or harmful?
ChatGPT，谷歌医生——有益还是有害？

16:10 - 16:30

Sustainable classification of IBD
IBD的可持续分类

16:30 - 16:50

Tandem Talk: Strategies to improve adherence
to therap
对话：提高治疗依从性的策略

17:10 - 17:30

How should we currently measure and define
long-term remission?
我们目前应该如何衡量和定义长期缓解？

2月21日

09:45 - 10:05

From Biomarkers to AI Monitoring
从生物标志物到人工智能监测

11:00 - 11:20

Novel technologies in endoscopy: is there an
additive benefit in patients with IBD?
内镜新技术：对IBD患者有额外的获益吗？

11:30 - 11:50

The role of endoscopy in the era of biomarkers
内镜检查在生物标志物时代的作用

12:10 - 12:30

Green endoscopy
绿色内镜

13:40 - 14:00

Tandem Talk: Mentally preparing the patient for
IBD surgery
对话：让患者做好IBD手术的心理准备

14:10 - 14:30

The sustainable anastomosis – new insights
about anastomotic healing
可持续吻合术——关于吻合口愈合的新见解

14:50 - 15:10

Tandem Talk: How do we define long-term
success in surgery?
对话：我们如何定义手术的长期成功？

15:40 - 16:00

Changing paradigms: trans-ethnic genetics in
IBD across different groups
正在改变的研究典范：不同群体中IBD的跨种族遗传学

16:10 - 16:20

The role of somatic mutations in intestinal
epithelial cells in IBD
肠上皮细胞体细胞突变在炎症性肠病中的作用

16:20 - 16:40

Environmental effects on spontaneous
mutations – epigenetics
环境对自发突变的影响——表观遗传学

2月22日

08:30 - 08:50

Tandem Talk: How far should we pursue our
targets to help patients live a normal life?
对话：为了帮助患者过上正常的生活，我们应该在多大程度上追求我们的目标？

10:50 - 11:10

Epidemiology in 2030 – prevalence, costs,
climate change
2030年的流行病学——患病率、成本、气候变化

11:20 - 11:40

Artificial Intelligence in Inflammatory Bowel
Disease: today and tomorrow, conclusions from the 9th ECCO Scientific Workshop
炎症性肠病中的人工智能：现在和未来，第九届ECCO科学研讨会的结论

12:20 - 12:50

ECCO Lecture: Lean, green and clean –
Sustainability in clinical practice and beyond
ECCO专题演讲：精益、绿色、清洁——临床实践及其他领域的可持续性

13:40 - 14:00

ESPGHAN-ECCO UC Guidelines update
ESPGHAN-ECCO溃疡性结肠炎指南更新

2月21日

09:18 - 09:24

DOP081：The EXTENT Study (Calculating the LEmann indeX using inTEstiNal ulTrasound): Results from an international expert Delphi consensus
DOP081：EXTENT研究（利用超声检查计算LEmann指数）：国际专家德尔菲共识的结果

14:40 - 14:50

OP17:Defining radiological healing in perianal fistulising Crohn’s Disease: a global modified Delphi consensus
口头报告17：定义肛周瘘管性克罗恩病的放射学愈合：全球改良的德尔菲共识

15:40 - 16:00

ECCO Consensus on Diet and Nutrition in IBD
ECCO关于IBD饮食和营养的共识

2月22日

09:30 - 09:50

Multi-society Diagnostic Guidelines
多协会诊断指南

12:00 - 12:20

ECCO Consensus on IBD in Low - and Middle -
Income Countries
ECCO关于中低收入国家IBD的共识

2月21日

16:35 - 16:45

OP21:MIF-CD74 signaling promotes intestinal LTi-like ILC3s activation and gut fibrosis via upregulating pSTAT3
OP21：MIF-CD74 信号通过上调 pSTAT3 促进肠道 LTi 样 ILC3 活化和肠道纤维化

上海交通大学医学院附属瑞金医院

16:45 - 16:55

OP22：NR1D1 Deficiency Induces CD47 Upregulation Impairing Macrophage Efferocytosis and Exacerbating Intestinal Inflammation in Ulcerative Colitis
OP22：NR1D1缺乏诱导CD47上调，损害巨噬细胞的胞吞作用并加剧溃疡性结肠炎的肠道炎症

华中科技大学医学院附属协和医院

数字口头报告（DOP）

2月20日

18:27 - 18:33

DOP008:High clinical and endoscopic remission rate with Vedolizumab in early CD patients: the 2nd interim analysis from a prospective multicenter interventional Study (EARLY CD)
DOP008：早期 CD 患者使用维多珠单抗后临床和内镜缓解率较高：前瞻性多中心介入研究 (EARLY CD) 的第 2 次中期分析

浙江大学医学院附属邵逸夫医院

17:57 - 18:03

DOP021:Appendectomy regulates intestinal flora-bile acid axis inhibits macrophage lipid metabolism and improves Ulcerative Colitis
DOP021：阑尾切除术调节肠道菌群-胆汁酸轴抑制巨噬细胞脂质代谢改善溃疡性结肠炎

天津医科大学总医院

18:27 - 18:33

DOP026:Porphyromonas gingivalis secreted htpG disrupts TLR4/ PAPSS2-mediated mucin sulfation and aggravates ulcerative colitis
DOP026：牙龈卟啉单胞菌分泌的 htpG 破坏 TLR4/PAPSS2 介导的粘蛋白硫酸化并加重溃疡性结肠炎

天津医科大学总医院

17:57 - 18:03

DOP039:Dietary methyl group donor intake alleviates the susceptibility to inflammatory bowel disease influenced by environmental pollution in a prospective cohort study
DOP039：前瞻性队列研究中膳食甲基供体摄入可减轻受环境污染影响的炎症性肠病的易感性

中南大学湘雅三医院

2月21日

08:30 - 08:36

DOP073：Gli1+ Mesenchymal Cells Drive Intestinal Fibrostenosis by Secreting SMOC2: A Biomarker and Therapeutic Target
DOP073：Gli1+间充质细胞通过分泌SMOC2驱动肠道纤维狭窄：生物标志物和治疗靶点

上海交通大学医学院附属瑞金医院

08:48 - 08:54

DOP058：Efficacy and Safety of Vedolizumab Combined with Upadacitinib in Moderate-to-Severe Ulcerative Colitis: A Multicenter, Prospective, Randomized Controlled Trial
DOP058：维多珠单抗联合乌帕替尼治疗中重度溃疡性结肠炎的疗效和安全性：一项多中心、前瞻性、随机对照试验

中山大学附属第六医院

09:06 - 09:12

DOP052:Etrasimod as induction and maintenance therapy in Asian patients with moderately to severely active Ulcerative Colitis: Results from the maintenance period of a randomised, double-blind, placebo-controlled, multi-centre Phase 3 study (ES101002)
DOP052：Etrasimod 作为中度至重度活动性溃疡性结肠炎亚洲患者的诱导和维持治疗：一项随机、双盲、安慰剂对照、多中心 3 期研究的维持期结果 (ES101002)

空军军医大学西京医院等国内多中心合作研究

18:15 - 18:21

DOP123：Linking microbial genes to mucosal metabolites uncovers host-microbial interactions during 5-ASA therapy for ulcerative colitis
DOP123：将微生物基因与黏膜代谢物联系起来揭示了5-ASA治疗溃疡性结肠炎期间宿主-微生物的相互作用

北京协和医院

18:21 - 18:27

DOP115：Exophiala dermatitidis aggravates colitis through the Syk-CARD9 signaling pathway
DOP115：皮炎外瓶霉通过Syk-CARD9信号通路加重结肠炎

四川大学华西医院

18:27 - 18:33

DOP125：CD11b−CD27− NK subsets account for NK-cell dysfunction in patients with inflammatory bowel disease
DOP125：CD11b−CD27− NK 亚群导致炎症性肠病患者的 NK 细胞功能障碍

重庆大学附属人民医院